Intervet Inc. announced yesterday the full U.S. Department of Agriculture license for Circumvent PCV (Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector), which provides a superior solution for the control and management of Porcine Circovirus Associated Disease (PCVAD).
The vaccine is labeled as "For use in healthy swine, 3 weeks of age or older, as an aid in the prevention of viremia and as an aid in the prevention of virus shedding caused by Porcine Circovirus."
Under field conditions, with tens of millions of doses used to date, the vaccine has been shown to reduce mortality substantially and, of equal or greater importance, to provide consistently superior growth performance through processing versus non-vaccinates.
Circumvent PCV can be used in pigs as early as three weeks of age. For optimal immune response pigs should receive two 2 cc doses given through intramuscular injection three weeks apart, with vaccinations suggested at three and six weeks of age.
"This vaccine has proven effective in field studies to significantly reduce mortality, morbidity and medication costs, while improving growth performance versus non-vaccinates," said John Foxx, Intervet marketing manager.